Project description
Host-directed approach to cure invasive fungal infections
Invasive fungal infections (IFIs) represent a major threat in immunocompromised and critically ill adult and paediatric patients. Experts believe that a host-directed approach could help to improve the current situation. The EU-funded HDM-FUN project proposes a transdisciplinary approach to identify critical factors for host-directed medical interventions in IFIs. The overall objective is to identify host-pathogen factors essential for immunotherapy and prophylaxis, so as to enable the design of novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in intensive care. HDM-FUN brings together leading scientists and clinical researchers to study genetics and transcription host factors, metabolome and microbiome immune modulators and host pathogen interactions at molecular and cellular level that determine the susceptibility and treatment outcome of patients with fungal infection.
Objective
Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptably high mortality and morbidity. Experts believe that a host directed approach is needed to overcome this problem. HDM-FUN proposes a transdisciplinary approach to identify host-pathogen factors (HPFs) needed for host directed medical interventions in IFI and will be the first of its kind.
The overall concept is to identify host-pathogen factors in the setting of immunotherapy and prophylaxis that will allow the design for tailored novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in the intensive care.
Specific objectives:
1. To identify host-pathogen factors that correlate with disease, and correlate them with preventive or immunotherapy- based strategies to stratify patients for personalized host-directed treatment options.
2. Two clinical trials of host-directed medicine approaches; an immunotherapy trial in patients with candidemia and a prospective observational trial for prophylaxis in patients with influenza at risk for aspergillosis.
3. To set-up a centrally managed biobank with samples of the patients enrolled in both clinical trials, and to standardize experimental procedures, protocols and centralize analysis.
4. To establish a unique infrastructure aimed to: explore host-directed medicine approaches in IFI, evaluate their impact on patients and health care, translate research efforts to clinical practice by designing point of care tests and teaching medical professionals.
HDM-FUN brings together top scientists and clinical researchers to unravel host factors (genetics and transcription), immune modulators (metabolome, microbiome), and host pathogen interactions (genetics, metabolomics, immunology, signalling pathways, phagosome biogenesis, and inflammasome regulation) that determine the susceptibility and outcome of patients with fungal infection.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (17)
75724 Paris
See on map
1011 Lausanne
See on map
60323 Frankfurt Am Main
See on map
97070 Wuerzburg
See on map
4704 553 Braga
See on map
06123 Perugia
See on map
70013 Irakleio
See on map
07745 Jena
See on map
400012 Cluj-Napoca
See on map
AB24 3FX ABERDEEN
See on map
27708 Durham Nc
See on map
3000 Leuven
See on map
5405 PB Uden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75015 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75006 Paris
See on map
53100 Siena
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
6525 XZ Nijmegen
See on map